Resisting Resistance: Maximizing the Durability of Antiretroviral Therapy (1998)

Editorials1 June 1998Resisting Resistance: Maximizing the Durability of Antiretroviral TherapyJon H. Condra, PhDJon H. Condra, PhDMerck Research Laboratories; West Point, PA 19486Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-11-199806010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the past 3 years, a veritable explosion of data has yielded new insight into the biology of HIV infection and the pathogenesis of AIDS. It is now well known that HIV infection, even during its long asymptomatic phase, is characterized by high rates of viral replication and destruction of CD4+ cells, which ultimately lead to immune deficiency, AIDS-defining illnesses, and death. Consequently, inhibition of viral replication has assumed primary importance in the control of AIDS.Simultaneously, a new class of potent antiviral drugs, HIV protease inhibitors, was introduced. Protease inhibitors have proven, for the first time, that potent, sustained ...References1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337:734-9. Google Scholar2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC): concurrent or sequential therapy in ZDV- experienced patients [Abstract]. Abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1997:I-89. Google Scholar3. Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A. Henry D. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update [Abstract]. Int Conf AIDS. 1996; 11:24. Google Scholar4. Lalezari J, Haubrich R, Burger HU, Beattie D, Donatacci L, Salgo MP. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV) plus HIVID (zalcitabine, ddC) [Abstract]. Int Conf AIDS. 1996; 11:29. Google Scholar5. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337:725-33. Google Scholar6. HIV/AIDS Surveillance Report. Atlanta, GA: Centers for Disease Control and Prevention; 1997; 9:22. Google Scholar7. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995; 267:483-9. Google Scholar8. Condra JH, Emini EA. Preventing HIV-1 drug resistance. Sci Med. 1997; 4:14-23. Google Scholar9. Condra JH, Holder DJ, Schleif WA, Chodakewitz JA, Massari FE, Blahy OM, et al. Bi-directional inhibition of HIV-1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors [Abstract]. Int Conf AIDS. 1996; 11:19. Google Scholar10. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995; 374:569-71. Google Scholar11. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996; 2:760-6. Google Scholar12. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type-1 protease inhibitor. J Virol. 1996; 70:8270-6. Google Scholar13. Jacobsen H, Hanggi M, Ott M, Duncan IB, Andreoni M, Vella S, et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis. 1996; 173:1379-87. Google Scholar14. Patick AK, Mo H, Markowitz M, Appelt K, Wu B, Musick L, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother. 1996; 40:292-7. Google Scholar15. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother. 1995; 39:1704-10. Google Scholar16. Vacca JP, Condra JH. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today. 1997; 2:261-72. Google Scholar17. Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic [Abstract]. Abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1997:LB-2. Google Scholar18. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med. 1998; 128:906-911. Google Scholar19. Condra JH, Holder DJ, Graham DJ, Shivaprakash M, Laird DT, Schleif WA, et al. Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir [Abstract]. Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. Antiviral Therapy Quarterly. San Diego: University of California, San Diego; 1997:31-2. Google Scholar20. Hertogs K, Mellors JW, Schel P, Van Cauwenberghe A, Larder B, Kemp S, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates [Abstract]. Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, 1-5 February 1998, Chicago. Alexandria, VA: Foundation for Retrovirology and Human Health; 1998:153. Google Scholar Author, Article, and Disclosure InformationAuthors: Jon H. Condra, PhDAffiliations: Merck Research Laboratories; West Point, PA 19486Corresponding Author: Jon H. Condra, PhD, Department of Antiviral Research, Merck & Co., Inc., WP26-339, West Point, PA 19486. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAvoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infectionHow Does Expert Advice Impact Genotypic Resistance Testing in Clinical Practice?Comparison of three Kinetic Models of HIV-1 Infection: Implications for Optimization of TreatmentRelationship between Levels of Indinavir in Hair and Virologic Response to Highly Active Antiretroviral TherapyLouis Bernard, MD, Albert Vuagnat, MD, Gilles Peytavin, MD, Marie-Charlotte Hallouin, MD, Damien Bouhour, MD, Thu Huyen Nguyen, MD, Jean Louis Vildé, MD, François Bricaire, MD, Gilles Raguin, MD, Pierre de Truchis, MD, David Ghez, MD, Michel Duong, MD, and Christian Perronne, MD, PhDVirulence and Reduced Fitness of Simian Immunodeficiency Virus with the M184V Mutation in Reverse TranscriptaseClinical utility of HIV-1 genotyping and expert advice: the Havana trialThe polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistanceIntrabodies as Antiviral AgentsComparative Analysis of HIV Type 1 Genotypic Resistance across Antiretroviral Trial Treatment RegimensFactors associated with the successful modification of antiretroviral therapyHIV-1 Genotypic Resistance Patterns Predict Response to saquinavir–ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had FailedAndrew R. Zolopa, MD, Robert W. Shafer, MD, Ann Warford, PhD, Jose G. Montoya, MD, Phillip Hsu, BA, David Katzenstein, MD, Thomas C. Merigan, MD, and Brad Efron, PhDEmergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitorsHuman anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDSEfavirenz, Nelfinavir, and Stavudine Rescue Combination Therapy in HIV-1–Positive Patients Heavily Pretreated With Nucleoside Analogues and Protease InhibitorsEfavirenz, Nelfinavir, and Stavudine Rescue Combination Therapy in HIV-1–Positive Patients Heavily Pretreated With Nucleoside Analogues and Protease InhibitorsHigher antiviral activity of antiretroviral regimens including protease inhibitors9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Therapy Prolongs Survival of Infant Macaques Inoculated with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPAVirologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavirThe Costs, Clinical Benefits, and Cost-Effectiveness of Screening for Cervical Cancer in HIV-Infected WomenSue J. Goldie, MD, MPH, Milton C. Weinstein, PhD, Karen M. Kuntz, ScD, and Kenneth A. Freedberg, MD, MScAnal Intraepithelial Neoplasia (AIN) 1 June 1998Volume 128, Issue 11Page: 951-954KeywordsAIDSAmino acidsClinical trialsDrugsGeneticsHIVMutationProtease inhibitorsReverse transcriptase inhibitorsViral replication ePublished: 15 August 2000 Issue Published: 1 June 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...